Trial reportThe patient2022
Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13.
Trial report in The patient, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Trial
- First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Repotrectinib inThe New England journal of medicine · 2024Trial
- Review
- Feasibility of patient-reported outcomes collection in clinical routine at a radiotherapy department.Acta oncologica (Stockholm, Sweden) · 2026Article
- Financial difficulty among patients with cancer participating in clinical trials and its association with patient survival and quality of life.Journal of the National Cancer Institute · 2025Article
- Article
- Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies.BMC medical research methodology · 2025Article
- Recovery of quality of life in 574 patients with inoperable lung cancer undergoing (chemo)radiotherapy.Clinical and translational radiation oncology · 2025Article
- FURLONG study: reply on the patient reported outcome measures and thresholds.The Lancet regional health. Western Pacific · 2025Article
- Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®).Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Post-Surgery: A Scoping Review.International journal of medical sciences · 2025Article
- Optimizing lung cancer surgery in the elderly: sublobar resection versus lobectomy for early-stage non-small cell lung cancer patients aged 80 and above.Discover oncology · 2024Article
- Effects of Symptom Burden on Quality of Life in Patients with Lung Cancer.Current oncology (Toronto, Ont.) · 2024Article
- Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial.Targeted oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhen determining if changes on patient-reported outcome (PRO) scores in clinical trials convey a meaningful treatment benefit, statistical significance tests alone may not communicate the patient perspective. Appraising within-patient changes on PRO scores against established thresholds can determine if improvements or deteriorations experienced by individuals are meaningful. To evaluate the appropriateness of thresholds for interpreting meaningful improvements and deterioration within individuals on the European Organisation for Research and Treatment of Cancer (EORTC) 30-item core instrument (QLQ-C30) and 13-item lung cancer module (QLQ-LC13), a series of psychometric methods were applied to data from a phase III randomized controlled clinical trial in non-small cell lung cancer.
methodsAnchor-based methods of empirical cumulative distribution functions and classification statistics were employed using change scores from Baseline to Week 7 using changes on the QLQ-C30 Global Health Status item as an anchor. Distribution-based methods of one-half standard deviation and standard error of measurement identified the minimum amount of change each domain score can reliably measure.
resultsWhile the correlations between the domain scores and the anchor item were modest in size (i.e., r ≥ 0.30 for only 5 of 24 domains), consideration of multiple methods along with the magnitude of possible step changes on the score allowed for patterns to emerge. The triangulation process planned a priori resulted in different methods being the source for different domain scores. Absolute values of the proposed thresholds ranged from 11.11 to 33.33, and all resulted in the same classifications for all EORTC domains, except QLQ-C30 Fatigue, as would the 10-point threshold that is traditionally used.
conclusionThis study confirms the appropriateness of the 10-point EORTC score threshold generally used by the field for interpreting within-patient changes, but the thresholds proposed from this study enhance interpretability by corresponding to only observable locations along the domain score scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.